This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Infectious Diseases, Other  • Choroidal Neovascularization  • Pediatric Ophthalmology  • Retinal/ Chorioretinal Disorders  • Pediatrics  • Pediatrics, Other  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic

Joseph D. Benevento, MD; Rama D. Jager, MD, MBA; A. Gwendolyn Noble, MD, PhD; Paul Latkany, MD; William F. Mieler, MD; Mari Sautter, BA; Sanford Meyers, MD; Marilyn Mets, MD; Michael A. Grassi, MD; Peter Rabiah, MD; Kenneth Boyer, MD; Charles Swisher, MD; Rima McLeod, MD; for the Toxoplasmosis Study Group

Arch Ophthalmol. 2008;126(8):1152-1156.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Choroidal neovascular membranes (CNVMs) rarely complicate toxoplasmic chorioretinitis^1-5 and are managed by observation; antiparasitic, anti-inflammatory medication; laser photocoagulation; surgical excision; or photodynamic therapy, with variable outcomes. As occurs with CNVMs secondary to age-related macular degeneration, Toxoplasma gondii increases expression of hypoxia-inducible factor–1 in tissue cultures along with vascular endothelial growth factor (VEGF).⁶

Report of Cases

Two patients with prior ocular toxoplasmosis had active CNVMs with subretinal blood and fluid on clinical examination and ocular coherence tomography (OCT) and hyperfluorescence with leakage documented on fluorescein angiogram (FA). Each was treated with off-label intravitreal injections of ranibizumab (Genentech, Inc, South San Francisco, California) and . . . [Full Text of this Article]

Case 1

Case 2

Comment

AUTHOR INFORMATION